Treatment with intravenous immunoglobulin modulates coagulation- and complement-related pathways in COVID-19 patients.

ABSTRACT:

Introduction

Intravenous immunoglobulin (IVIG) is a therapy that uses pooled immunoglobulins from thousands of different donors. While it is primarily used to treat immunodeficiency and autoimmune diseases due to its immunomodulatory properties, IVIG has also been used as an off-label therapy for respiratory infections, including COVID-19. Clinical data regarding the efficacy of IVIG for COVID-19 has been controversial, and although some smaller studies have shown beneficial effects, others including a large randomized trial found no significant clinical impact but noted detrimental secondary effects.

Methods

We describe the first proteomic analysis from the plasma of COVID-19 patients treated with IVIG, as well as clinical outcomes.

Results

Patients that received IVI

SUBMITTER: McGrosso D 

PROVIDER: S-EPMC12350128 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature